Citations

Clear

3042 citation(s) found for "Kumar, S".

MicroRNA-326 Regulates Profibrotic Functions of Transforming Growth Factor-β in Pulmonary Fibrosis
Das, Sudipta , Kumar, Manish , Negi, Vinny , Pattnaik, Bijay , Prakash, Y. S. , Agrawal, Anurag , Ghosh, Balaram , Prakash, Y S

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | November 26, 2013 | Volume: 50 | Issue: 5 | Pages: 882-892

10.1165/rcmb.2013-0195oc | PMID 24279830 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal disorder resulting from the progressive remodeling of lungs, with no known effective treatment. Although transforming growth factor (TGF)-β has a well-established role in lung fibrosis, clinical experience with neutralizing antibodies to TGF-β has been disappointing, and strategies to directly suppress TGF-β1 secretion are needed. In this study we used a combination of in silico, in vitro, and in vivo approaches to identify microRNAs involved in TGF-β1 regulation and to validate the role of miR-326 in pulmonary fibrosis.We show that hsa-miR-326 regulates TGF-β1 expression and that hsa-miR-326 levels are inversely correlated to TGF-β1 protein levels in multiple human cell lines. The increase in TGF-β1 expression during the progression of bleomycin-induced lung fibrosis in mice was associated with loss of mmu-miR-326. Restoration of mmu-miR-326 levels by intranasal delivery of miR-326 mimics was sufficient to inhibit TGF-β1 expression and attenuate the fibrotic response. Moreover, human IPF lung specimens had markedly diminished miR-326 expression as compared with nonfibrotic lungs. Additional targets of miR-326 controlling TGF-β signaling and fibrosis-related pathways were identified, and miR-326 was found to down-regulate profibrotic genes, such as Ets1, Smad3, and matrix metalloproteinase 9, whereas it up-regulates antifibrotic genes, such as Smad7. Our results suggest for the first time that miR-326 plays a key role in regulating TGF-β1 expression and other profibrotic genes and could be useful in developing better therapeutic strategies for alleviating lung fibrosis.
Long‐term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
Kourelis, Taxiarchis , Kumar, Shaji , Srivastava, Geetika , Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Leung, Nelson , Kyle, Robert A. , Russell, Stephen J. , Dingli, David , Lust, John A., Lin, Yi , Kapoor, Prashant , Dispenzieri, Angela , Kourelis, Taxiarchis V, Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | November 22, 2013 | Volume: 89 | Issue: 3 | Pages: 302-305

10.1002/ajh.23634 | PMID 24265187 Get It

There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥1 year (39 vs. 13 months, P < 0.05); there was no difference in PFS for those treated for 1–2 years as compared to ≥2 years. Among those taking lenalidomide for ≥1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P < 0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long‐term disease control. Am. J. Hematol. 89:302–305, 2014. © 2013 Wiley Periodicals, Inc.
Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
Kapoor, Prashant , Kumar, Shaji , Dispenzieri, Angela , Lacy, Martha Q. , Dingli, David , Russell, Stephen J. , Hayman, Suzanne R. , Lust, John A., Leung, Nelson , Lin, Yi , Zeldenrust, Steven R., McCurdy, Arleigh , Greipp, Philip R., Kyle, Robert A. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S. Vincent , Gertz, Morie A. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi , McCurdy, Arleigh

Mayo Clinic

Journal of Clinical Oncology | November 18, 2013 | Volume: 31 | Issue: 36 | Pages: 4529-4535

10.1200/jco.2013.49.0086 | PMID 24248686 Get It

Purpose To study the impact of achieving stringent complete response (sCR), an increasingly attainable goal, after autologous stem-cell transplantation (ASCT) in patients with multiple myeloma (MM). Patients and Methods Maximal response rates were determined in 445 consecutive patients who underwent ASCT within 12 months of diagnosis of MM. The patients achieving varying degrees of complete response (CR) are the focus of our study. Results One hundred and nine patients (25%) achieved sCR after ASCT. The median overall survival (OS) rate from the time of transplantation for patients attaining sCR was not reached (NR), in contrast to those patients achieving conventional complete response (CR; n = 37; OS, 81 months) or near CR (nCR; n = 91; OS, 60 months; P < .001). Five-year OS rates were 80%, 53%, and 47% for sCR, CR, and nCR, respectively. The median time to progression (TTP) from ASCT of patients achieving sCR was significantly longer (50 months) than TTP of patients achieving CR or nCR (20 months and 19 months, respectively). On multivariable analysis, post-ASCT response of sCR was an independent prognostic factor for survival (hazard ratio, 0.44; 95% CI, 0.25 to 0.80; versus CR; P = .008), in addition to proliferation rate, pre-ASCT cytogenetics, and performance status. OS rates of patients attaining sCR continued to remain superior at 2-year landmark (median, NR v 70 months for conventional CR group; P = .007). Conclusion Improved long-term outcome is seen after ASCT with achievement of sCR when compared with lesser degrees of responses. Myeloma trials reporting the response rates should identify patients achieving sCR and CR separately, owing to markedly disparate outcomes of the two categories.
AT‐101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
Paulus, Aneel , Chitta, Kasyapa S., Akhtar, Sharoon , Personett, David, Miller, Kena C., Thompson, Kevin J. , Carr, Jennifer M., Kumar, Shaji , Ansell, Stephen M. , Dispenzieri, Angela , Reeder, Craig B. , Rivera, Candido E., Foran, James M. , Chanan‐Khan, Asher , Chitta, Kasyapa, Carr, Jennifer, Mikhael, Joseph R., Chanan-Khan, Asher, Roy, Vivek , Mıkhael, Joseph , Dispenzieri, Angela , Thompson, Kevin J , Paulus, Aneel

Mayo Clinic

British Journal of Haematology | November 18, 2013 | Volume: 164 | Issue: 3 | Pages: 352-365

10.1111/bjh.12633 | PMID 24236538 Get It

SummaryMultiple myeloma, the second most common haematological malignancy in the U.S., is currently incurable. Disruption of the intrinsic apoptotic pathway by BCL2 and MCL1 upregulation is observed in >80% of myeloma cases and is associated with an aggressive clinical course. Remarkably, there is no approved drug with the ability to target BCL2 or MCL1. Thus, we investigated the anti‐tumour effects of a pan‐BCL2 inhibitor, AT‐101, which has high binding specificity for BCL2 and MCL1 in preclinical models of plasma cell cancers (Multiple myeloma and Waldenström macroglobulinaemia). Gene expression and immunoblot analysis of six plasma cell cancer models showed upregulation of BCL2 family members. AT‐101 was able to downregulate BCL2 and MCL1 in all plasma cell cancer models and induced apoptotic cell death in a caspase‐dependent manner by altering mitochondrial membrane permeability. This cytotoxic effect and BCL2 downregulation were further potentiated when AT‐101 was combined with lenalidomide/dexamethasone (LDA). NanoString nCounter mRNA quantification and Ingenuity Pathways Analysis revealed differential changes in the CCNA2, FRZB, FYN, IRF1, PTPN11 genes in LDA‐treated cells. In summary, we describe for the first time the cellular and molecular events associated with the use of AT‐101 in combination with lenalidomide/dexamethasone in preclinical models of plasma cell malignancy.
H alomonas sulfidaeris ‐dominated microbial community inhabits a 1.8 km‐deep subsurface C ambria
Dong, Yiran , Kumar, Charu G., Kim, Pan‐Jun , Miller, P., Price, Nathan D. , Flynn, Theodore M. , Sanford, Robert A. , Krapac, Ivan G., Locke, Randall A. , Hong, Pei‐Ying , Tamaki, Hideyuki , Mackie, Roderick I. , Hernandez, Alvaro G. , Wright, Chris , Mikel, Mark A. , Walker, Jared, Sivaguru, Mayandi , Fried, Glenn , Yannarell, Anthony C. , Fouke, Bruce W. , Chia, Nicholas , Cann, Isaac , Liu, Wen‐Tso , Price, Nathan D

Mayo Clinic

Environmental Microbiology | November 14, 2013 | Volume: 16 | Issue: 6 | Pages: 1695-1708

10.1111/1462-2920.12325 | PMID 24238218 Get It

Summary A low‐diversity microbial community, dominated by the γ ‐proteobacterium H alomonas sulfidaeris , was detected in samples of warm saline formation porewater collected from the C ambrian Mt. S imon S andstone in the I llinois B asin of the N orth A merican M idcontinent (1.8 km/5872 ft burial depth, 50° C , pH 8, 181 bars pressure). These highly porous and permeable quartz arenite sandstones are directly analogous to reservoirs around the world targeted for large‐scale hydrocarbon extraction, as well as subsurface gas and carbon storage. A new downhole low‐contamination subsurface sampling probe was used to collect in situ formation water samples for microbial environmental metagenomic analyses. Multiple lines of evidence suggest that this H . sulfidaeris ‐dominated subsurface microbial community is indigenous and not derived from drilling mud microbial contamination. Data to support this includes V 1‐ V 3 pyrosequencing of formation water and drilling mud, as well as comparison with previously published microbial analyses of drilling muds in other sites. Metabolic pathway reconstruction, constrained by the geology, geochemistry and present‐day environmental conditions of the Mt . S imon S andstone, implies that H . sulfidaeris ‐dominated subsurface microbial community may utilize iron and nitrogen metabolisms and extensively recycle indigenous nutrients and substrates. The presence of aromatic compound metabolic pathways suggests this microbial community can readily adapt to and survive subsurface hydrocarbon migration.
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance
Kumar, Shaji , Jacques, Richard , Ng, Alvin C., McCready, Louise K., Farr, Joshua N. , Zhang, Wei Yan , Rajkumar, S. Vincent , Drake, Matthew T.

Mayo Clinic

Blood | November 14, 2013 | Volume: 123 | Issue: 5 | Pages: 647-649

10.1182/blood-2013-05-505776 | PMID 24227822 Get It

Key PointsMGUS patients have significantly increased cortical bone porosity and reduced bone strength relative to matched controls.
Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis
Singh, Siddharth , Garg, Sushil Kumar , Iyer, Prasad G. , El‐Serag, Hashem B. , Singh, Preet Paul

Mayo Clinic

Gut | November 12, 2013 | Volume: 63 | Issue: 8 | Pages: 1229-1237

10.1136/gutjnl-2013-305997 | PMID 24221456 Get It

Background and aims Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta-analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BO-HGD) in patients with BO. Methods We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and/or BO-HGD in patients with BO. Summary ORs with 95% CIs were estimated. Results We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4% PPI users). On meta-analysis, PPI use was associated with a 71% reduction in risk of OAC and/or BO-HGD in patients with BO (adjusted OR 0.29; 95% CI 0.12 to 0.79). There was a trend towards a dose–response relationship with PPI use for >2–3 years protective against OAC or BO-HGD (three studies; PPI use >2–3 years vs <2–3 years: OR 0.45 (95% CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4% on H2RAs), and both studies did not show a significant effect. Conclusions Based on meta-analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.
Health-related quality of life in children and young adults with post-thrombotic syndrome: Results from a cross-sectional study
Kumar, Riten , Rodriguez, Vilmarie , Matsumoto, Jane M., Khan, Shakila P. , Weaver, Amy L. , McBane, Robert D. , Beebe, Timothy J. , Heit, John A. , McBane, Robert , Kumar, Riten

Mayo Clinic

Pediatric Blood & Cancer | November 6, 2013 | Volume: 61 | Issue: 3 | Pages: 546-551

10.1002/pbc.24840 | PMID 24347376 Get It

Clinical Practice Guideline: Bell's Palsy Executive Summary
Baugh, Reginald F. , Basura, Gregory J. , Ishii, Lisa E. , Schwartz, Seth, Drumheller, Caitlin, Burkholder, Rebecca, Deckard, Nathan A. , Dawson, Cindy , Driscoll, Colin L. W., Gillespie, M. Boyd , Gurgel, Richard K. , Halperin, John , Kumar, Kaparaboyna Ashok, Micco, Alan G. , Munsell, Debra, Rosenbaum, Steven, Vaughan, William, Gurgel, Richard Klaus , Khalid, Ayesha N.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 4, 2013 | Volume: 149 | Issue: 5 | Pages: 656-663

10.1177/0194599813506835 | PMID 24190889 Get It

The American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO‐HNSF) has published a supplement to this issue featuring the new Clinical Practice Guideline: Bell's Palsy. To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 11 recommendations developed encourage accurate and efficient diagnosis and treatment and, when applicable, facilitate patient follow‐up to address the management of long‐term sequelae or evaluation of new or worsening symptoms not indicative of Bell's palsy. There are myriad treatment options for Bell's palsy; some controversy exists regarding the effectiveness of several of these options, and there are consequent variations in care. In addition, there are numerous diagnostic tests available that are used in the evaluation of patients with Bell's palsy. Many of these tests are of questionable benefit in Bell's palsy. Furthermore, while patients with Bell's palsy enter the health care system with facial paresis/paralysis as a primary complaint, not all patients with facial paresis/paralysis have Bell's palsy. It is a concern that patients with alternative underlying etiologies may be misdiagnosed or have an unnecessary delay in diagnosis. All of these quality concerns provide an important opportunity for improvement in the diagnosis and management of patients with Bell's palsy.
Clinical Practice Guideline: Bell's Palsy
Baugh, Reginald F. , Basura, Gregory J. , Ishii, Lisa E. , Schwartz, Seth, Drumheller, Caitlin, Burkholder, Rebecca, Deckard, Nathan A. , Dawson, Cindy , Driscoll, Colin L. W., Gillespie, M. Boyd , Gurgel, Richard K. , Halperin, John , Kumar, Kaparaboyna Ashok, Micco, Alan G. , Munsell, Debra, Rosenbaum, Steven, Vaughan, William, Gurgel, Richard Klaus , Khalid, Ayesha N.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 4, 2013 | Volume: 149 | Issue: S3 | Pages: No page available

10.1177/0194599813505967 | PMID 24189771 Get It

Objective Bell's palsy, named after the Scottish anatomist, Sir Charles Bell, is the most common acute mono‐neuropathy, or disorder affecting a single nerve, and is the most common diagnosis associated with facial nerve weakness/paralysis. Bell's palsy is a rapid unilateral facial nerve paresis (weakness) or paralysis (complete loss of movement) of unknown cause. The condition leads to the partial or complete inability to voluntarily move facial muscles on the affected side of the face. Although typically self‐limited, the facial paresis/paralysis that occurs in Bell's palsy may cause significant temporary oral incompetence and an inability to close the eyelid, leading to potential eye injury. Additional long‐term poor outcomes do occur and can be devastating to the patient. Treatments are generally designed to improve facial function and facilitate recovery. There are myriad treatment options for Bell's palsy, and some controversy exists regarding the effectiveness of several of these options, and there are consequent variations in care. In addition, numerous diagnostic tests available are used in the evaluation of patients with Bell's palsy. Many of these tests are of questionable benefit in Bell's palsy. Furthermore, while patients with Bell's palsy enter the health care system with facial paresis/paralysis as a primary complaint, not all patients with facial paresis/paralysis have Bell's palsy. It is a concern that patients with alternative underlying etiologies may be misdiagnosed or have unnecessary delay in diagnosis. All of these quality concerns provide an important opportunity for improvement in the diagnosis and management of patients with Bell's palsy. Purpose The primary purpose of this guideline is to improve the accuracy of diagnosis for Bell's palsy, to improve the quality of care and outcomes for patients with Bell's palsy, and to decrease harmful variations in the evaluation and management of Bell's palsy. This guideline addresses these needs by encouraging accurate and efficient diagnosis and treatment and, when applicable, facilitating patient follow‐up to address the management of long‐term sequelae or evaluation of new or worsening symptoms not indicative of Bell's palsy. The guideline is intended for all clinicians in any setting who are likely to diagnose and manage patients with Bell's palsy. The target population is inclusive of both adults and children presenting with Bell's palsy. Action Statements The development group made a strong recommendation that (a) clinicians should assess the patient using history and physical examination to exclude identifiable causes of facial paresis or paralysis in patients presenting with acute‐onset unilateral facial paresis or paralysis, (b) clinicians should prescribe oral steroids within 72 hours of symptom onset for Bell's palsy patients 16 years and older, (c) clinicians should not prescribe oral antiviral therapy alone for patients with new‐onset Bell's palsy, and (d) clinicians should implement eye protection for Bell's palsy patients with impaired eye closure. The panel made recommendations that (a) clinicians should not obtain routine laboratory testing in patients with new‐onset Bell's palsy, (b) clinicians should not routinely perform diagnostic imaging for patients with new‐onset Bell's palsy, (c) clinicians should not perform electrodiagnostic testing in Bell's palsy patients with incomplete facial paralysis, and (d) clinicians should reassess or refer to a facial nerve specialist those Bell's palsy patients with (1) new or worsening neurologic findings at any point, (2) ocular symptoms developing at any point, or (3) incomplete facial recovery 3 months after initial symptom onset. The development group provided the following options : (a) clinicians may offer oral antiviral therapy in addition to oral steroids within 72 hours of symptom onset for patients with Bell's palsy, and (b) clinicians may offer electrodiagnostic testing to Bell's palsy patients with complete facial paralysis. The development group offered the following no recommendations : (a) no recommendation can be made regarding surgical decompression for patients with Bell's palsy, (b) no recommendation can be made regarding the effect of acupuncture in patients with Bell's palsy, and (c) no recommendation can be made regarding the effect of physical therapy in patients with Bell's palsy.